See All Slides - tctmd.com

Slides

Presentation TCT 2015

FIH Data Review Regarding Degree and Duration of DCB Efficacy in De Novo Lesions: Is There a Class Effect?

Presenter: Greg L. Kaluza, Thomas Zeller, Gunnar Tepe

October 12, 2015

Presentation TCT 2015

Essentials of Quality and Compliance in Research

Presenter: David A. Cox, Thomas D. Stuckey, Kate Dalton

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate: Is CREST-2 a Worthwhile Use of Precious Resources? The CREST-2 Trial Is the Right Trial at the Right Time!

Presenter: William A. Gray, D. Christopher Metzger, Gary S. Roubin

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Paravalvular Leak Closure: New Devices and the State of the Art

Presenter: Ziyad M. Hijazi, Robert J. Sommer

October 14, 2015

Presentation TCT 2013

Assessing the Sidebranch after Crossover Stenting (with and without Pre-dilatation): Use Angiography and Common Sense!

Presenter: Jeffrey Moses

October 28, 2013

Presentation TCT 2013

Pros and Cons of SYNTAX Score II

Presenter: Davide Capodanno

October 28, 2013

Presentation TCT 2013

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Presenter: Bernard Chevalier

October 28, 2013

Presentation TCT 2013

Synergy of Transradial Intervention and Same
Day Discharge: Why and for Whom?

Presenter: Matthew Price

October 28, 2013

Advertisement

Slides

FIH Data Review Regarding Degree and Duration of DCB Efficacy in De Novo Lesions: Is There a Class Effect?

Essentials of Quality and Compliance in Research

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Debate: Is CREST-2 a Worthwhile Use of Precious Resources? The CREST-2 Trial Is the Right Trial at the Right Time!

Reversal Agents for Factor Xa Inhibitors

Paravalvular Leak Closure: New Devices and the State of the Art

Assessing the Sidebranch after Crossover Stenting (with and without Pre-dilatation): Use Angiography and Common Sense!

Pros and Cons of SYNTAX Score II

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Synergy of Transradial Intervention and Same
Day Discharge: Why and for Whom?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content